Antonio Addis

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7642323/antonio-addis-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92 2,909 26 53 g-index

125 3,333 6 4.34 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
92	Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019 <i>Frontiers in Medicine</i> , 2022 , 9, 820757	4.9	3
91	Drug Prescriptions in the Outpatient Management of COVID-19: Evidence-Based Recommendations Versus Real Practice <i>Frontiers in Pharmacology</i> , 2022 , 13, 825479	5.6	1
90	The Italian Network for Monitoring Medication Use During Pregnancy (MoM-Net): Experience and Perspectives. <i>Frontiers in Pharmacology</i> , 2021 , 12, 699062	5.6	O
89	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. <i>BioDrugs</i> , 2021 , 35, 749-764	7.9	1
88	The Standard of Care Definitions on COVID-19 Pharmacological Clinical Trials: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2021 , 12, 749514	5.6	
87	Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study. <i>Medicine (United States)</i> , 2021 , 100, e25943	1.8	2
86	Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
85	Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 649472	5.6	6
84	Real world data to identify target population for new CAR-T therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 78-85	2.6	O
83	Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. <i>BMJ Paediatrics Open</i> , 2021 , 5, e000985	2.4	1
82	Drug discontinuation in pregnant women with psoriasis: The PSO-MOTHER cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 904-912	2.6	1
81	Lasciate ogni speranza voi che non sperimentate: il Recovery collaborative group e il Recovery fund. <i>Medico E Bambino</i> , 2020 , 39, 551-552	0.4	1
80	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 195-199	1.2	3
79	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. <i>Drug Safety</i> , 2020 , 43, 1-5	5.1	7
78	Using GRADE methodology to assess innovation of new medicinal products in Italy. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 93-105	3.8	13
77	In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. <i>BioDrugs</i> , 2020 , 34, 55-64	7.9	2
76	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. <i>Drug Safety</i> , 2019 , 42, 1437-1447	5.1	16

75	Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 497-509	4.1	10
74	Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. <i>BMJ Open</i> , 2019 , 9, e0337	28,	13
73	Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. <i>Drug Safety</i> , 2019 , 42, 683-687	5.1	О
7 ²	Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions. <i>Recenti Progressi in Medicina</i> , 2019 , 110, 195-202	0.7	O
71	Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Nephrology</i> , 2018 , 31, 321-332	4.8	12
70	Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 245-253	4.6	20
69	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014. <i>Frontiers in Endocrinology</i> , 2018 , 9, 95	5.7	16
68	Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. <i>Archives of Disease in Childhood</i> , 2018 , 103, 1163-1167	2.2	6
67	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. <i>Clinical Epidemiology</i> , 2018 , 10, 203-213	5.9	6
66	Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review. <i>Journal of Clinical Epidemiology</i> , 2018 , 101, 5-16	5.7	1
65	Information needs on precision medicine: a survey of Italian health care professionals. <i>Annali Delllistituto Superiore Di Sanita</i> , 2018 , 54, 316-323	1.6	1
64	Can systematic reviews contribute to regulatory decisions?. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 507-509	2.8	6
63	Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. <i>BMJ Open</i> , 2017 , 7, e011637	3	22
62	Folic Acid for the Prevention of Neural Tube Defects. <i>JAMA Pediatrics</i> , 2017 , 171, 709-710	8.3	2
61	Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region. <i>BioDrugs</i> , 2017 , 31, 117-124	7.9	12
60	Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry. <i>British Journal of Dermatology</i> , 2017 , 176, 1331-1338	4	11
59	Qual [il Giusto Place in Therapy Dell'olmesartan?. <i>Global & Regional Health Technology Assessment</i> , 2017 , 4, grhta.5000264	0.2	
58	Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 299-308	4.5 .e16	59

57	The Italian reference sites of the European innovation partnership on active and healthy ageing: Progetto Mattone Internazionale as an enabling factor. <i>Annali Delllistituto Superiore Di Sanita</i> , 2017 , 53, 60-69	1.6	11
56	A Nutritional Approach to the Prevention of Cancer: from Assessment to Personalized Intervention. <i>Translational Medicine @ UniSa</i> , 2015 , 13, 33-41	0.5	3
55	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014 , 44, 304-23	13.6	112
54	International collaboration to assess the risk of Guillain Barr Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. <i>Vaccine</i> , 2013 , 31, 4448-58	4.1	78
53	Drotrecogin alfa (activated) in severe sepsis. Lancet Infectious Diseases, The, 2013, 13, 107-8	25.5	
52	The pharmacovigilance program on natalizumab in Italy: 2 years of experience. <i>Neurological Sciences</i> , 2009 , 30 Suppl 2, S163-5	3.5	14
51	The Italian Horizon Scanning Project. European Journal of Clinical Pharmacology, 2009, 65, 775-81	2.8	17
50	Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. <i>Dermatology</i> , 2008 , 217, 365-73	4.4	167
49	Natalizumab: a country-based surveillance program. <i>Neurological Sciences</i> , 2008 , 29 Suppl 2, S235-7	3.5	9
48	Clinical evidence continuous medical education: a randomised educational trial of an open access e-learning program for transferring evidence-based information - ICEKUBE (Italian Clinical Evidence Knowledge Utilization Behaviour Evaluation) - study protocol. <i>Implementation Science</i> , 2008 , 3, 37	8.4	14
47	Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. <i>Intensive Care Medicine</i> , 2007 , 33, 426-34	14.5	66
46	Response to the letter by Williams et al <i>Intensive Care Medicine</i> , 2007 , 33, 1490-1491	14.5	
45	Using Clinical Evidence in a national continuing medical education program in Italy. <i>PLoS Medicine</i> , 2007 , 4, e113	11.6	9
44	Folic acid: a public-health challenge. <i>Lancet, The</i> , 2006 , 367, 2057	40	3
43	European Clinical Trials Directive: the Italian position. <i>Lancet, The</i> , 2004 , 363, 1651-2	40	6
42	PatientsTcharges in Slovakia. <i>Lancet, The</i> , 2004 , 363, 1651	40	5
41	Current national initiatives about drug policies and cost control in Europe: the Italy example. <i>Journal of Ambulatory Care Management</i> , 2004 , 27, 127-31	0.8	14
40	A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. <i>Canadian Journal of Psychiatry</i> , 2003 , 48, 106-10	4.8	87

(2000-2003)

39	Toward estimating the impact of changes in immigrantsTinsurance eligibility on hospital expenditures for uncompensated care. <i>BMC Health Services Research</i> , 2003 , 3, 1	2.9	34
38	Clinical Evidence: a useful tool for promoting evidence-based practice?. <i>BMC Health Services Research</i> , 2003 , 3, 24	2.9	9
37	Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. <i>Journal of Allergy and Clinical Immunology</i> , 2003 , 111, 479-83	11.5	58
36	New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. <i>Pharmacoepidemiology and Drug Safety</i> , 2002 , 11, 721-6	2.6	14
35	Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. <i>American Journal of Perinatology</i> , 2002 , 19, 311-6	3.3	57
34	Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. <i>Clinical Therapeutics</i> , 2002 , 24, 302-16	3.5	216
33	New drug treatment for asthma: clinical versus statistical significance. <i>Journal of Pediatrics</i> , 2002 , 140, 484; author reply 484-5	3.6	3
32	Adverse effects of prenatal methimazole exposure. <i>Teratology</i> , 2001 , 64, 262-6		178
31	Fetal effects of cocaine: an updated meta-analysis. Reproductive Toxicology, 2001, 15, 341-69	3.4	125
30	Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. <i>American Journal of Psychiatry</i> , 2001 , 158, 1728-30	11.9	188
29	Drug use during pregnancy. Lancet, The, 2001, 357, 800	40	5
28	Drug use during pregnancy. <i>Lancet, The</i> , 2001 , 357, 800	40	7
27	Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. <i>Psychological Medicine</i> , 2000 , 30, 89-94	6.9	88
26	Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. <i>American Journal of Medical Genetics Part A</i> , 2000 , 95, 302-6		81
25	Prospective, controlled, multicentre study of loperamide in pregnancy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000 , 14, 185-7		45
24	Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. <i>New England Journal of Medicine</i> , 2000 , 343, 445-6	59.2	32
23	Risk classification systems for drug use during pregnancy: are they a reliable source of information?. <i>Drug Safety</i> , 2000 , 23, 245-53	5.1	84
22	Your cardiac patient wants to become a mother. Risk considerations and advice Part Iyour cardiac patient asks advice on a possible pregnancy. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2000 , 1, 605-12		

21	Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). European Journal of Clinical Pharmacology, 1999 , 55, 1-6	2.8	46
20	High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. <i>Teratology</i> , 1999 , 59, 7-11		58
19	Use of nimesulide in children. Lancet, The, 1999 , 354, 1034	40	2
18	Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 1999 , 104, 953-6	11.5	20
17	Informing women about drugs they take during pregnancy: promoting consumersTdrug information as integral part of care. <i>International Journal of Clinical Pharmacy</i> , 1998 , 20, 236-7		1
16	The safety of omeprazole during pregnancy: a multicenter prospective controlled study. <i>American Journal of Obstetrics and Gynecology</i> , 1998 , 179, 727-30	6.4	56
15	A prospective controlled multicentre study of clarithromycin in pregnancy. <i>American Journal of Perinatology</i> , 1998 , 15, 523-5	3.3	75
14	Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. <i>BMJ: British Medical Journal</i> , 1998 , 317, 839-43		215
13	Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 1336-9	5.9	173
12	Therapeutic approach to hypertension during pregnancy. <i>Canadian Family Physician</i> , 1998 , 44, 1245-7	0.9	1
11	Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals. <i>Annals of Pharmacotherapy</i> , 1997 , 31, 423-8	2.9	27
10	Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995). <i>Pharmacoeconomics</i> , 1997 , 12, 685-94	4.4	18
9	Cisapride use during human pregnancy: a prospective, controlled multicenter study. <i>Digestive Diseases and Sciences</i> , 1997 , 42, 1848-52	4	23
8	Acid-suppressing drugs during pregnancy. <i>Canadian Family Physician</i> , 1997 , 43, 1923-4, 1927	0.9	5
7	Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. <i>Pharmacoeconomics</i> , 1997 , 12, 286-96	4.4	24
6	Tuberculosis during pregnancy. <i>Canadian Family Physician</i> , 1996 , 42, 1461-2	0.9	1
5	Drug use in pregnancy and lactation: the work of a regional drug information center. <i>Annals of Pharmacotherapy</i> , 1995 , 29, 632-3	2.9	12
4	Vitamin A supplementation during pregnancy in developed countries. <i>Lancet, The</i> , 1995 , 345, 736-7	40	1

LIST OF PUBLICATIONS

3	Decrease in [3H]hemicholinium binding to high-affinity choline uptake sites in deafferented striatum: restoration by oxiracetam. <i>Brain Research</i> , 1990 , 530, 156-60	3.7	6	
2	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. <i>Therapeutic Innovation and Regulatory Science</i> ,216847901882088	1.2	1	
1	Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?. Global & Regional Health Technology Assessment,8, 114-119	0.2	0	